Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing

Arulogun, Suzanne O.; Brian, Duncan; Goradia, Harshita; Cooney, Aaron; Menne, Tobias; Koo, RayMun; O’Neill, Aideen T.; Vos, Josephine M.I.; Pratt, Guy; Turner, Deborah; Marshall, Kirsty; Manos, Kate; Anderson, Claire; Gavriatopoulou, Maria; Kyriakou, Charalampia; Kersten, Marie J.; Minnema, Monique C.; Koutoumanou, Eirini; El-Sharkawi, Dima; Linton, Kim; Talaulikar, Dipti; McCarthy, Helen; Bishton, Mark; Follows, George; Wechalekar, Ashutosh; D’Sa, Shirley P.

Abstract

Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival.

A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicentre, retrospective cohort analysis.

Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p<0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% vs 82%, respectively (p=0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000mg/m2 compared with those receiving 800-999mg/m2 (p=0.04). In the relapsed cohort, those who received doses of <600mg/m2 had poorer PFS outcomes compared with those who received ≥600mg/m2 (p=0.02).

Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.

Citation

Arulogun, S. O., Brian, D., Goradia, H., Cooney, A., Menne, T., Koo, R., …D’Sa, S. P. (2023). Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing. American Journal of Hematology, 98(5), 750-759. https://doi.org/10.1002/ajh.26895

• Journal Article Type: Article
• Acceptance Date: Feb 20, 2023
• Online Publication Date: Mar 3, 2023
• Publication Date: 2023-05
• Deposit Date: Feb 22, 2023
• Publicly Available Date: Mar 4, 2024
• Journal: American Journal of Hematology
• Print ISSN: 0361-8609
• Electronic ISSN: 1096-8652
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 98
• Issue: 5
• Pages: 750-759
• DOI: https://doi.org/10.1002/ajh.26895
• Keywords: Chemotherapy, immunotherapy, outcomes research, non-Hodgkin lymphoma, neoplasia-myeloma and other plasma cell dyscrasias
• Public URL: https://nottingham-repository.worktribe.com/output/17658967
• Publisher URL: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26895
• Additional Information: This is the peer reviewed version of the following article: Arulogun, SO, Brian, D, Goradia, H, et al. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing. Am J Hematol. 2023; 98( 5): 750- 759., which has been published in final form at https://onlinelibrary.wiley.com/action/showCitFormats?doi=10.1002%2Fajh.26895